NFKB1 and B-cell chronic lymphocytic leukemia: qPCR analyses demonstrated that ATO did not upregulate NFKB1 mRNA expression at any of the times studied (Figure 5E), in agreement with the reported inactivation of NF-κB upon ATO treatment of primary CLL cells [10].